| Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA |
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. |
globenewswire.com |
2025-05-16 17:12:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Sana Biotechnology, Inc. (SANA) Investors - Lead Plaintiff Deadline on May 20, 2025 |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148884&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 13:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025 |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148791&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 11:15:00 |
Czytaj oryginał (ang.) |
| SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Sana Biotechnology, Inc. to Contact the Firm Today! |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-16 11:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA |
NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. |
prnewswire.com |
2025-05-16 09:45:00 |
Czytaj oryginał (ang.) |
| Sana Biotechnology, Inc. (SANA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 20, 2025 Deadline |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148745&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 20:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Urges Sana Biotechnology, Inc. (SANA) Shareholders to Act Before Lead Plaintiff Deadline May 20, 2025 |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148732&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 19:30:00 |
Czytaj oryginał (ang.) |
| SANA DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / WHY: New York, N.Y., May 15, 2025. |
accessnewswire.com |
2025-05-15 19:02:00 |
Czytaj oryginał (ang.) |
| Lost Money on Sana Biotechnology, Inc. (SANA)? Urged to Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148723&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 18:45:00 |
Czytaj oryginał (ang.) |
| May 20, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SANA |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). |
globenewswire.com |
2025-05-15 17:55:00 |
Czytaj oryginał (ang.) |
| Sana Biotechnology, Inc. (SANA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 20, 2025 Deadline |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148701&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 15:45:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Sana Biotechnology, Inc. (SANA) Over Securities Violations - Contact Levi & Korsinsky Today |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148618&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 11:15:00 |
Czytaj oryginał (ang.) |
| SANA Stockholders Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-15 11:00:00 |
Czytaj oryginał (ang.) |
| Investors in Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA |
NEW YORK , May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-05-15 09:45:00 |
Czytaj oryginał (ang.) |
| Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148537&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-14 19:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options |
globenewswire.com |
2025-05-14 18:50:00 |
Czytaj oryginał (ang.) |
| May 20, 2025 Deadline Approaching: Join Class Action Against Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148522&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-14 18:15:00 |
Czytaj oryginał (ang.) |
| SANA DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA |
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / WHY: New York, N.Y., May 14, 2025. |
accessnewswire.com |
2025-05-14 17:32:00 |
Czytaj oryginał (ang.) |
| Contact Levi & Korsinsky by May 20, 2025 to Join Class Action Against Sana Biotechnology, Inc. (SANA) |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148486&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-14 13:45:00 |
Czytaj oryginał (ang.) |
| Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference |
SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 45th Annual Health Care Conference at 3:10 p.m. ET on Monday, March 3, 2025. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| There May Still Be Time to Get in on These 3 Trending Biotechs |
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms. |
marketbeat.com |
2025-01-20 10:15:25 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-18 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-16 22:45:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-10 14:00:00 |
Czytaj oryginał (ang.) |
| SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data |
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients. |
zacks.com |
2025-01-10 13:21:08 |
Czytaj oryginał (ang.) |
| Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. |
globenewswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-08 14:00:00 |
Czytaj oryginał (ang.) |
| Sana Biotechnology skyrockets 200% on positive diabetes study data |
Sana Biotechnology Inc skyrocketed over 200% on Wednesday after unveiling positive results from its first in-human diabetes trial. No safety issues were observed four weeks after transplanting Sana's UP421 allogeneic primary islet cell therapy into a type 1 diabetes patient, a statement said. |
proactiveinvestors.com |
2025-01-08 13:32:20 |
Czytaj oryginał (ang.) |
| Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success |
Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense. |
seekingalpha.com |
2025-01-08 12:30:55 |
Czytaj oryginał (ang.) |
| Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why |
On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression. |
benzinga.com |
2025-01-08 11:27:09 |
Czytaj oryginał (ang.) |
| Citi keeps $15 target on Sana, says data 'potentially transformative' |
Citi says that while the wait for Sana Biotechnology's initial type 1 diabetes data was long, the "reward was well worth it as Sana has delivered what looks to be potentially transformative data," the analyst tells investors in a research note. The data demonstrate a "major scientific advance" for type 1 diabetes patients as it suggests Sana's hypoimmune edits permit islet cell transplant survival in the absence of immunosuppression, the analyst tells investors in a research note. Citi believes the implications extend beyond type 1 diabetes and islet cells though, and could potentially be applied broadly within the allogeneic field. The firm anticipates the stock could continue to appreciate after the open today and keeps a Buy rating on the name with a $15 price target. Sana in premarket trading is up 274%, or $4.52, to $6.17. |
https://thefly.com |
2025-01-08 11:11:07 |
Czytaj oryginał (ang.) |
| H.C. Wainwright ups Sana target after 'best case scenario' data |
H.C. Wainwright raised the firm's price target on Sana Biotechnology to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% from 10% based on today's data and for SC291 for autoimmune diseases to 20% from 15% based on the Phase 1 data and progress from competitor allogeneic CAR-T programs in the space. The first patient dosed with hypoimmune islet cells showcased cell survive and function without immunosuppression, the analyst tells investors in a research note. H.C. Wainwright says the patient met all the primary and secondary trial endpoints. It views the data as the "best case scenario" for the initial type 1 diabetes update. |
https://thefly.com |
2025-01-08 11:08:24 |
Czytaj oryginał (ang.) |
| This Biotech Stock Just Soared 240%. Why It Can Go Higher. |
The shares are at about $5 now, and strategists see a chance they could go to $10. |
barrons.com |
2025-01-08 09:25:00 |
Czytaj oryginał (ang.) |
| Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression |
First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression |
globenewswire.com |
2025-01-07 18:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-06 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-05 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-03 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-02 12:25:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-31 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-30 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-29 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-12-27 18:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-26 19:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-24 18:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-17 13:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-16 16:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-15 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-13 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-11 16:30:00 |
Czytaj oryginał (ang.) |
| Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus |
Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. |
seekingalpha.com |
2024-12-04 17:36:38 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-12-03 21:23:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-27 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-26 18:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-11-25 22:05:00 |
Czytaj oryginał (ang.) |
| Sana Biotechnology to Present at December 2024 Investor Conferences |
SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. |
globenewswire.com |
2024-11-25 18:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA |
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-22 12:00:00 |
Czytaj oryginał (ang.) |